-
UK PM dismisses Russian threats as Ukraine allies gather in Kyiv
-
India declare on 503-9 after Jurel hundred
-
Attacks on Red Cross in DR Congo making Ebola fight 'harder'
-
Kremlin says UK preventing peace by giving missile info to Ukraine
-
Oil falls ahead of US plan for economic war on Iran
-
Springboks change half-backs for second All Blacks Test
-
Millions of Teslas recalled in China over door handle safety
-
Jurel hits 95 not out as India reach 475-8 at tea in Sri Lanka Test
-
IUX Launches New Education Webinar Series to Support Traders’ Financial Literacy
-
Ingebrigtsen buoyed by fourth in Diamond League comeback
-
Dutch say won't participate in 'no longer' neutral Eurovision
-
Kenyans get creative to join manga cosplay craze
-
Kenyan farmers turn to bugs as organic demand grows
-
Pant, Jurel half-centuries take India past 400 in Sri Lanka Test
-
'His feet are his pillars': Nepal para swimmer gives all for Asian glory
-
Migrants, rescue ships face threats, harassment at sea: aid group
-
New Zealand moves to ban social media for under-16s
-
UEFA's Ceferin tells Infantino to go, but 'not interested' in replacing him
-
Hyundai union back in wage talks after rare full-day strike
-
Oil falls as Trump pledges economic war on Iran
-
Shein grapples with EU backlash, but clients keep coming
-
Yamashita marches to nine-shot win in LPGA Canadian Women's Open
-
Key facts about Chinese-founded fast-fashion giant Shein
-
Gauff powers past Pegula to win US Open warm-up in Cincinnati
-
Shein to make market debut in Hong Kong in September
-
Japan's Olympic figure skating heroes to wed
-
Fils tops Tiafoe to claim first ATP Masters title in Cincinnati
-
Cummins eyes ODI return ahead of 'big' South Africa Test series
-
Gauff powers past Pegula to win Cincinnati WTA 1000 crown
-
RMTG's Cellgenic Division Launches Natural Killer (NK) Cell Product Line for International Markets
-
WyoTech Represented on the National Stage at the Great Race
-
Electrovaya Commences Factory Acceptance Testing of Cell Manufacturing Line for Jamestown Cell Manufacturing Facility
-
SK Tes Publishes 2025 Sustainability Report: Resilience in the Circular Economy
-
Ferrari Purosangue Now Available to Rent in Miami
-
Electric Metals Launches Multi-Workstream Program to Strengthen Economics of the US$1.39 Billion North Star Manganese Project
-
Quorum Technologies Debuts Bioz Badges to Connect Researchers with Product Evidence
-
Oleria and Happiest Minds Partner to Accelerate Modern Identity Governance for AI-First Enterprises
-
Sinopec Achieves Solid Operating Results in the First Half of 2026
-
Global Education Communities Corp. Provides Update on the Atmosphere Project
-
Galway Metals Continues to Demonstrate Broad Gold Mineralization at Southwest Deposit; 2.0 g/t Gold Over 68.0 Metres
-
Start the New Year Right: Practical Life Resolutions
-
Cyber Enviro-Tech Announces Definitive Agreement With Air Power USA to Advance Global Clean Energy Commercialization As $45M Funding MOU Emerges Pending Consolidation of the Companies
-
Zide Opens Public Beta of Its Native AI Development Workspace - Code, Git, Issues, and CI in One App
-
ZTEST Electronics Inc. Announces the Grant of Stock Options to CEO and Directors
-
Black Book Announces 2026 Converged Clinical AI Platform Category and Market Assessment
-
Gold Terra Announces Sonic Drill Program to Evaluate Gold Content in Con Mine Historical Tailings, Yellowknife, NWT and Stock Options Grant
-
Amarc Announces CAD$20 Million Private Placement Financing
-
India police used excessive force during protests: Amnesty
-
Ukraine backers gather as war escalates, air defence runs low
-
Rookie La Sasso wins LIV season-ender as tour's future in doubt
Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025
OXFORD, GB AND GERMANTOWN, MD / ACCESS Newswire / June 9, 2025 / Barinthus Biotherapeutics plc announced that Bill Enright, CEO, will be presenting at the Investor Summit Virtual taking place on June 10.
About Barinthus Biotherapeutics
Barinthus Biotherapeutics (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic candidates for treating autoimmune and inflammatory diseases. Our guiding principle at the heart of Barinthus Bio is to help patients and their families by developing truly transformational and highly disease-specific immunotherapies that are potentially curative. Barinthus Bio's pipeline for I&I indications is enabled by our proprietary and highly differentiated platform for promoting immune tolerance, SNAP-TI, that is designed to guide a patient's T cells to a specific location to reduce inflammation and restore the natural state of immune non-responsiveness to healthy tissue. Our lead candidate, VTP-1000, is designed to restore immune non-responsiveness to gluten in patients with celiac disease and is currently in a Phase 1 clinical trial. Barinthus Bio's differentiated technology platform and therapeutic approach, coupled with deep scientific expertise and focus on clinical development, uniquely positions the company to navigate towards delivering treatments that improve the lives of people with autoimmune and inflammatory diseases. For more information, visit www.barinthusbio.com.
Event: Q2 Investor Summit
Presentation Time: June 10, 11:00 - 11:30 AM ET
Location: WEBCAST LINK
Conference Overview and Structure
The Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what your peers are doing in this market.
This quarter's event is focused on MicroCap companies who have a near-term catalyst and are undervalued.
Registration for Investors
To request free registration, please go to our website (https://investorsummitgroup.com/), and click the "Registration" button.
Sponsors:
AccessNewswire
PCG Advisory
QuoteMedia
AGP
MZ Group
News Compliments of ACCESSWIRE
For More Information
Please visit: https://investorsummitgroup.com/
Or, contact [email protected]
SOURCE: Investor Summit Group
View the original press release on ACCESS Newswire
G.P.Martin--AT